| (Values in U.S. Thousands) | Dec, 2025 | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 |
| Sales | 8,980 | 7,010 | 6,210 | 5,170 | 4,500 |
| Sales Growth | +28.10% | +12.88% | +20.12% | +14.89% | +80.72% |
| Net Income | -48,790 | -32,010 | -19,920 | -18,490 | -14,920 |
| Net Income Growth | -52.42% | -60.69% | -7.73% | -23.93% | -41.56% |
Inspiremd Inc (NSPR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
InspireMD Inc. is a medical device company focusing on the development and commercialization of its proprietary stent system technology, MGuard(TM). The Company's initial products are marketed for use mainly in patients with acute coronary syndromes, notably acute myocardial infarction and saphenous vein graft coronary interventions. It focuses on applying its technology to develop additional products used for other vascular procedures, specifically carotid and peripheral procedures. InspireMD Inc. is headquartered in Tel Aviv, Israel.
Fiscal Year End Date: 12/31